{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:14:32Z","timestamp":1793304872520,"version":"4.5.0"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CASHIPS seed grant"},{"name":"Hundred Talents Program Award from the Chinese Academy of Sciences"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900153"],"award-info":[{"award-number":["81900153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Liaoning Province Natural Science Foundation","doi-asserted-by":"crossref","award":["2022-YGJC-62"],"award-info":[{"award-number":["2022-YGJC-62"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01673-7","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T09:21:16Z","timestamp":1741684876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Circulating tumor DNA in lymphoma: technologies and applications"],"prefix":"10.1186","volume":"18","author":[{"given":"Lina","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1439-7606","authenticated-orcid":false,"given":"Hongcang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"11","key":"1673_CR1","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","volume":"4","author":"C Cancer","year":"2018","unstructured":"Global Burden of Disease, Cancer C, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553\u201368.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1673_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348.","journal-title":"Leukemia"},{"issue":"1","key":"1673_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-020-0113-2","volume":"5","author":"L Wang","year":"2020","unstructured":"Wang L, Qin W, Huo YJ, Li X, Shi Q, Rasko JEJ, Janin A, Zhao WL. Advances in targeted therapy for malignant lymphoma. Signal Transduct Target Ther. 2020;5(1):15.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"1673_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/d41573-019-00051-6","volume":"18","author":"K Chaudhari","year":"2019","unstructured":"Chaudhari K, Rizvi S, Syed BA. Non-hodgkin lymphoma therapy landscape. Nat Rev Drug Discov. 2019;18(9):663\u20134.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1673_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2016.205","volume":"14","author":"A Younes","year":"2017","unstructured":"Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, Advani R, Forero A, Morschhauser F, Kersten MJ, et al. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol. 2017;14(6):335\u201346.","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"1673_CR6","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood.2022015854","volume":"140","author":"L de Leval","year":"2022","unstructured":"de Leval L, Alizadeh AA, Bergsagel PL, Campo E, Davies A, Dogan A, Fitzgibbon J, Horwitz SM, Melnick AM, Morice WG, et al. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022;140(21):2193\u2013227.","journal-title":"Blood"},{"key":"1673_CR7","doi-asserted-by":"publisher","first-page":"102042","DOI":"10.1016\/j.ctrv.2020.102042","volume":"88","author":"AM Tun","year":"2020","unstructured":"Tun AM, Ansell SM. Immunotherapy in Hodgkin and non-hodgkin lymphoma: innate, adaptive and targeted immunological strategies. Cancer Treat Rev. 2020;88:102042.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1673_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617\u201329.","journal-title":"Am J Hematol"},{"issue":"7","key":"1673_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41408-021-00518-z","volume":"11","author":"R Mohty","year":"2021","unstructured":"Mohty R, Dulery R, Bazarbachi AH, Savani M, Hamed RA, Bazarbachi A, Mohty M. Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies. Blood Cancer J. 2021;11(7):126.","journal-title":"Blood Cancer J"},{"issue":"4","key":"1673_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-021-00456-w","volume":"11","author":"BD Cheson","year":"2021","unstructured":"Cheson BD, Nowakowski G, Salles G. Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer J. 2021;11(4):68.","journal-title":"Blood Cancer J"},{"issue":"3","key":"1673_CR11","first-page":"646","volume":"37","author":"SA Leon","year":"1977","unstructured":"Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646\u201350.","journal-title":"Cancer Res"},{"issue":"4","key":"1673_CR12","first-page":"1659","volume":"61","author":"S Jahr","year":"2001","unstructured":"Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659\u201365.","journal-title":"Cancer Res"},{"key":"1673_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cca.2013.05.022","volume":"424","author":"S El Messaoudi","year":"2013","unstructured":"El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta. 2013;424:222\u201330.","journal-title":"Clin Chim Acta"},{"key":"1673_CR14","doi-asserted-by":"crossref","unstructured":"Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466).","DOI":"10.1126\/scitranslmed.aat4921"},{"issue":"8","key":"1673_CR15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/15384047.2019.1598759","volume":"20","author":"A Kustanovich","year":"2019","unstructured":"Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Life and death of circulating cell-free DNA. Cancer Biol Ther. 2019;20(8):1057\u201367.","journal-title":"Cancer Biol Ther"},{"issue":"40","key":"1673_CR16","doi-asserted-by":"publisher","first-page":"E5503","DOI":"10.1073\/pnas.1508736112","volume":"112","author":"K Sun","year":"2015","unstructured":"Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH, Chan WK, Ma ES, Chan SL, Cheng SH, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112(40):E5503\u20135512.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1673_CR17","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.7150\/thno.45554","volume":"10","author":"D Han","year":"2020","unstructured":"Han D, Li R, Shi J, Tan P, Zhang R, Li J. Liquid biopsy for infectious diseases: a focus on microbial cell-free DNA sequencing. Theranostics. 2020;10(12):5501\u201313.","journal-title":"Theranostics"},{"issue":"8","key":"1673_CR18","doi-asserted-by":"publisher","first-page":"e0185522","DOI":"10.1128\/jcm.01855-22","volume":"61","author":"SY Park","year":"2023","unstructured":"Park SY, Chang EJ, Ledeboer N, Messacar K, Lindner MS, Venkatasubrahmanyam S, Wilber JC, Vaughn ML, Bercovici S, Perkins BA, et al. Plasma microbial cell-free DNA sequencing from over 15,000 patients identified a broad spectrum of pathogens. J Clin Microbiol. 2023;61(8):e0185522.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"1673_CR19","first-page":"100259","volume":"3","author":"Q Gao","year":"2022","unstructured":"Gao Q, Zeng Q, Wang Z, Li C, Xu Y, Cui P, Zhu X, Lu H, Wang G, Cai S, et al. Circulating cell-free DNA for cancer early detection. Innov (Camb). 2022;3(4):100259.","journal-title":"Innov (Camb)"},{"issue":"SupplSuppl","key":"1673_CR20","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.placenta.2013.11.014","volume":"35","author":"ES Taglauer","year":"2014","unstructured":"Taglauer ES, Wilkins-Haug L, Bianchi DW. Review: cell-free fetal DNA in the maternal circulation as an indication of placental health and disease. Placenta. 2014;35(SupplSuppl):S64\u201368.","journal-title":"Placenta"},{"issue":"1","key":"1673_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11357-022-00590-8","volume":"45","author":"L Kananen","year":"2023","unstructured":"Kananen L, Hurme M, Burkle A, Moreno-Villanueva M, Bernhardt J, Debacq-Chainiaux F, Grubeck-Loebenstein B, Malavolta M, Basso A, Piacenza F, et al. Circulating cell-free DNA in health and disease - the relationship to health behaviours, ageing phenotypes and metabolomics. Geroscience. 2023;45(1):85\u2013103.","journal-title":"Geroscience"},{"issue":"1","key":"1673_CR22","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1038\/s41467-018-07466-6","volume":"9","author":"J Moss","year":"2018","unstructured":"Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, Samet Y, Maoz M, Druid H, Arner P, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9(1):5068.","journal-title":"Nat Commun"},{"issue":"6","key":"1673_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Consortium C. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745\u201359.","journal-title":"Ann Oncol"},{"issue":"4","key":"1673_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/bjh.17796","volume":"195","author":"S Borchmann","year":"2021","unstructured":"Borchmann S. Liquid biopsy in Hodgkin lymphoma - moving beyond the proof of principle. Br J Haematol. 2021;195(4):493\u20134.","journal-title":"Br J Haematol"},{"issue":"1","key":"1673_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12943-024-01947-7","volume":"23","author":"Z Huang","year":"2024","unstructured":"Huang Z, Fu Y, Yang H, Zhou Y, Shi M, Li Q, Liu W, Liang J, Zhu L, Qin S, et al. Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application. Mol Cancer. 2024;23(1):36.","journal-title":"Mol Cancer"},{"issue":"4","key":"1673_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3324\/haematol.2018.206177","volume":"104","author":"D Rossi","year":"2019","unstructured":"Rossi D, Spina V, Bruscaggin A, Gaidano G. Liquid biopsy in lymphoma. Haematologica. 2019;104(4):648\u201352.","journal-title":"Haematologica"},{"issue":"1","key":"1673_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","volume":"3","author":"M Roschewski","year":"2022","unstructured":"Roschewski M, Rossi D, Kurtz DM, Alizadeh AA, Wilson WH. Circulating tumor DNA in lymphoma: principles and future directions. Blood Cancer Discov. 2022;3(1):5\u201315.","journal-title":"Blood Cancer Discov"},{"issue":"10091","key":"1673_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-hodgkin lymphoma. Lancet. 2017;390(10091):298\u2013310.","journal-title":"Lancet"},{"key":"1673_CR29","doi-asserted-by":"crossref","unstructured":"Silkenstedt E, Salles G, Campo E, Dreyling M. B-cell non-hodgkin lymphomas. Lancet. 2024.","DOI":"10.1016\/S0140-6736(23)02705-8"},{"issue":"10","key":"1673_CR30","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","volume":"16","author":"Y Miao","year":"2019","unstructured":"Miao Y, Medeiros LJ, Li Y, Li J, Young KH. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16(10):634\u201352.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1673_CR31","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group","year":"1997","unstructured":"A clinical evaluation of the International Lymphoma Study Group. Classification of non-hodgkin\u2019s lymphoma. The Non-hodgkin\u2019s lymphoma classification project. Blood. 1997;89(11):3909\u201318.","journal-title":"Blood"},{"issue":"14","key":"1673_CR32","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","volume":"129","author":"D Rossi","year":"2017","unstructured":"Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S, Deambrogi C, Spina V, Bruscaggin A, Favini C, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017;129(14):1947\u201357.","journal-title":"Blood"},{"key":"1673_CR33","doi-asserted-by":"crossref","unstructured":"Zou H, Liu W, Wang X, Wang Y, Wang C, Qiu C, Liu H, Shan D, Xie T, Huang W et al. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. J Immunother Cancer. 2024;12(3).","DOI":"10.1136\/jitc-2023-008450"},{"issue":"7996","key":"1673_CR34","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","volume":"625","author":"SK Alig","year":"2024","unstructured":"Alig SK, Shahrokh Esfahani M, Garofalo A, Li MY, Rossi C, Flerlage T, Flerlage JE, Adams R, Binkley MS, Shukla N, et al. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling. Nature. 2024;625(7996):778\u201387.","journal-title":"Nature"},{"issue":"2","key":"1673_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481\u2013e494415.","journal-title":"Cell"},{"issue":"6769","key":"1673_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311.","journal-title":"Nature"},{"issue":"25","key":"1673_CR37","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937\u201347.","journal-title":"N Engl J Med"},{"issue":"5","key":"1673_CR38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390.","journal-title":"Nat Med"},{"issue":"15","key":"1673_CR39","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396\u2013407.","journal-title":"N Engl J Med"},{"issue":"4","key":"1673_CR40","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, Wang JQ, Schmitz R, Morin RD, Tang J, et al. A probabilistic classification Tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551\u2013e568514.","journal-title":"Cancer Cell"},{"issue":"364","key":"1673_CR41","doi-asserted-by":"publisher","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","volume":"8","author":"F Scherer","year":"2016","unstructured":"Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, Lovejoy AF, Chabon JJ, Klass DM, Liu CL, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.","journal-title":"Sci Transl Med"},{"issue":"4","key":"1673_CR42","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41587-022-01222-4","volume":"40","author":"MS Esfahani","year":"2022","unstructured":"Esfahani MS, Hamilton EG, Mehrmohamadi M, Nabet BY, Alig SK, King DA, Steen CB, Macaulay CW, Schultz A, Nesselbush MC, et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nat Biotechnol. 2022;40(4):585\u201397.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"1673_CR43","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1586\/14737159.2015.1019476","volume":"15","author":"SV Bratman","year":"2015","unstructured":"Bratman SV, Newman AM, Alizadeh AA, Diehn M. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Rev Mol Diagn. 2015;15(6):715\u20139.","journal-title":"Expert Rev Mol Diagn"},{"issue":"9","key":"1673_CR44","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","volume":"119","author":"R Kridel","year":"2012","unstructured":"Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, Gunawardana J, Jenkins CE, Cochrane C, Ben-Neriah S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119(9):1963\u201371.","journal-title":"Blood"},{"issue":"5","key":"1673_CR45","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1182\/blood.2019002385","volume":"136","author":"P Pararajalingam","year":"2020","unstructured":"Pararajalingam P, Coyle KM, Arthur SE, Thomas N, Alcaide M, Meissner B, Boyle M, Qureshi Q, Grande BM, Rushton C, et al. Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood. 2020;136(5):572\u201384.","journal-title":"Blood"},{"issue":"19","key":"1673_CR46","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","volume":"123","author":"J Zhang","year":"2014","unstructured":"Zhang J, Jima D, Moffitt AB, Liu Q, Czader M, Hsi ED, Fedoriw Y, Dunphy CH, Richards KL, Gill JI, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 2014;123(19):2988\u201396.","journal-title":"Blood"},{"issue":"12","key":"1673_CR47","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/ng.2468","volume":"44","author":"C Love","year":"2012","unstructured":"Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44(12):1321\u20135.","journal-title":"Nat Genet"},{"issue":"12","key":"1673_CR48","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/ng.2469","volume":"44","author":"J Richter","year":"2012","unstructured":"Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012;44(12):1316\u201320.","journal-title":"Nat Genet"},{"issue":"7418","key":"1673_CR49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature11378","volume":"490","author":"R Schmitz","year":"2012","unstructured":"Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116\u201320.","journal-title":"Nature"},{"issue":"8","key":"1673_CR50","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1182\/blood.2022016534","volume":"141","author":"N Thomas","year":"2023","unstructured":"Thomas N, Dreval K, Gerhard DS, Hilton LK, Abramson JS, Ambinder RF, Barta S, Bartlett NL, Bethony J, Bhatia K, et al. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood. 2023;141(8):904\u201316.","journal-title":"Blood"},{"issue":"12","key":"1673_CR51","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","volume":"133","author":"BM Grande","year":"2019","unstructured":"Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K, et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019;133(12):1313\u201324.","journal-title":"Blood"},{"key":"1673_CR52","doi-asserted-by":"crossref","unstructured":"Yi S, Yan Y, Jin M, Bhattacharya S, Wang Y, Wu Y, Yang L, Gine E, Clot G, Chen L et al. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022;132(3).","DOI":"10.1172\/JCI153283"},{"issue":"4706","key":"1673_CR53","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.3874430","volume":"228","author":"Y Tsujimoto","year":"1985","unstructured":"Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228(4706):1440\u20133.","journal-title":"Science"},{"issue":"4","key":"1673_CR54","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/ijc.23958","volume":"124","author":"F Schuler","year":"2009","unstructured":"Schuler F, Dolken L, Hirt C, Kiefer T, Berg T, Fusch G, Weitmann K, Hoffmann W, Fusch C, Janz S, et al. Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. Int J Cancer. 2009;124(4):958\u201363.","journal-title":"Int J Cancer"},{"issue":"6","key":"1673_CR55","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","volume":"131","author":"MR Green","year":"2018","unstructured":"Green MR. Chromatin modifying gene mutations in follicular lymphoma. Blood. 2018;131(6):595\u2013604.","journal-title":"Blood"},{"issue":"7360","key":"1673_CR56","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10351","volume":"476","author":"RD Morin","year":"2011","unstructured":"Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, et al. Frequent mutation of histone-modifying genes in non-hodgkin lymphoma. Nature. 2011;476(7360):298\u2013303.","journal-title":"Nature"},{"issue":"8","key":"1673_CR57","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nrc1409","volume":"4","author":"PG Isaacson","year":"2004","unstructured":"Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer. 2004;4(8):644\u201353.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1673_CR58","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","volume":"31","author":"E Zucca","year":"2020","unstructured":"Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, et al. Marginal zone lymphomas: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17\u201329.","journal-title":"Ann Oncol"},{"issue":"2","key":"1673_CR59","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/joim.13423","volume":"292","author":"MM B\u00fchler","year":"2022","unstructured":"B\u00fchler MM, Martin-Subero JI, Pan-Hammarstr\u00f6m Q, Campo E, Rosenquist R. Towards precision medicine in lymphoid malignancies. J Intern Med. 2022;292(2):221\u201342.","journal-title":"J Intern Med"},{"issue":"6","key":"1673_CR60","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood.2022018719","volume":"142","author":"K Dreval","year":"2023","unstructured":"Dreval K, Hilton LK, Cruz M, Shaalan H, Ben-Neriah S, Boyle M, Collinge B, Coyle KM, Duns G, Farinha P, et al. Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns. Blood. 2023;142(6):561\u201373.","journal-title":"Blood"},{"issue":"7","key":"1673_CR61","doi-asserted-by":"publisher","first-page":"100516","DOI":"10.1016\/j.modpat.2024.100516","volume":"37","author":"I Fern\u00e1ndez-Miranda","year":"2024","unstructured":"Fern\u00e1ndez-Miranda I, Pedrosa L, Gonz\u00e1lez-Rinc\u00f3n J, Espinet B, de la Cruz Vicente F, Climent F, G\u00f3mez S, Royuela A, Camacho FI, Mart\u00edn-Acosta P, et al. Generation and external validation of a histologic transformation risk model for patients with Follicular lymphoma. Mod Pathol. 2024;37(7):100516.","journal-title":"Mod Pathol"},{"key":"1673_CR62","doi-asserted-by":"crossref","unstructured":"Enemark MH, Hemmingsen JK, Jensen ML, Kridel R, Ludvigsen M. Molecular biomarkers in prediction of high-grade transformation and outcome in patients with follicular lymphoma: a comprehensive systemic review. Int J Mol Sci. 2024;25(20).","DOI":"10.3390\/ijms252011179"},{"issue":"10","key":"1673_CR63","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.neo.2018.08.012","volume":"20","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Liu W, Xu Z, Zhu H, Xiao D, Su W, Zeng R, Feng Y, Duan Y, Zhou J, et al. Analysis of genomic alteration in primary central nervous system lymphoma and the expression of some related genes. Neoplasia. 2018;20(10):1059\u201369.","journal-title":"Neoplasia"},{"issue":"1","key":"1673_CR64","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","volume":"13","author":"J Radke","year":"2022","unstructured":"Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L, Uhrig S, H\u00fcbschmann D, Toprak UH, L\u00f3pez C, et al. The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun. 2022;13(1):2558.","journal-title":"Nat Commun"},{"issue":"2","key":"1673_CR65","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.annonc.2022.11.002","volume":"34","author":"I Hern\u00e1ndez-Verdin","year":"2023","unstructured":"Hern\u00e1ndez-Verdin I, Kirasic E, Wienand K, Mokhtari K, Eimer S, Loiseau H, Rousseau A, Paillassa J, Ahle G, Lerintiu F, et al. Molecular and clinical diversity in primary central nervous system lymphoma. Ann Oncol. 2023;34(2):186\u201399.","journal-title":"Ann Oncol"},{"issue":"1","key":"1673_CR66","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5581\/1516-8484.20120013","volume":"34","author":"M Bellei","year":"2012","unstructured":"Bellei M, Chiattone CS, Luminari S, Pesce EA, Cabrera ME, de Souza CA, Gabus R, Zoppegno L, Zoppegno L, Milone J, et al. T-cell lymphomas in South America and europe. Rev Bras Hematol Hemoter. 2012;34(1):42\u20137.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"4","key":"1673_CR67","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3324\/haematol.2017.182444","volume":"103","author":"MM Ji","year":"2018","unstructured":"Ji MM, Huang YH, Huang JY, Wang ZF, Fu D, Liu H, Liu F, Leboeuf C, Wang L, Ye J, et al. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. Haematologica. 2018;103(4):679\u201387.","journal-title":"Haematologica"},{"issue":"2","key":"1673_CR68","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, Muto H, Tsuyama N, Sato-Otsubo A, Okuno Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171\u20135.","journal-title":"Nat Genet"},{"issue":"9","key":"1673_CR69","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","volume":"123","author":"O Odejide","year":"2014","unstructured":"Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9):1293\u20136.","journal-title":"Blood"},{"issue":"9","key":"1673_CR70","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, Pan CM, Hu Y, Cai CP, Dong Y, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat Genet. 2015;47(9):1061\u20136.","journal-title":"Nat Genet"},{"issue":"4","key":"1673_CR71","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","volume":"27","author":"R Crescenzo","year":"2015","unstructured":"Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27(4):516\u201332.","journal-title":"Cancer Cell"},{"issue":"2","key":"1673_CR72","doi-asserted-by":"publisher","first-page":"101416","DOI":"10.1016\/j.xcrm.2024.101416","volume":"5","author":"YH Huang","year":"2024","unstructured":"Huang YH, Qiu YR, Zhang QL, Cai MC, Yu H, Zhang JM, Jiang L, Ji MM, Xu PP, Wang L, et al. Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes. Cell Rep Med. 2024;5(2):101416.","journal-title":"Cell Rep Med"},{"issue":"26","key":"1673_CR73","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1200\/JCO.2005.55.013","volume":"23","author":"D Re","year":"2005","unstructured":"Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23(26):6379\u201386.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1673_CR74","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s00277-022-04949-x","volume":"101","author":"M Maco","year":"2022","unstructured":"Maco M, Kupcova K, Herman V, Ondeckova I, Kozak T, Mocikova H, Havranek O. Czech Hodgkin lymphoma study G: circulating tumor DNA in Hodgkin lymphoma. Ann Hematol. 2022;101(11):2393\u2013403.","journal-title":"Ann Hematol"},{"issue":"10","key":"1673_CR75","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","volume":"2","author":"S Sobesky","year":"2021","unstructured":"Sobesky S, Mammadova L, Cirillo M, Drees EEE, Mattlener J, D\u00f6rr H, Altm\u00fcller J, Shi Z, Br\u00f6ckelmann PJ, Weiss J, et al. In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease detection. Med. 2021;2(10):1171\u2013e11931111.","journal-title":"Med"},{"issue":"22","key":"1673_CR76","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","volume":"131","author":"V Spina","year":"2018","unstructured":"Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131(22):2413\u201325.","journal-title":"Blood"},{"issue":"1","key":"1673_CR77","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41375-019-0541-6","volume":"34","author":"AK Desch","year":"2020","unstructured":"Desch AK, Hartung K, Botzen A, Brobeil A, Rummel M, Kurch L, Georgi T, Jox T, Bielack S, Burdach S, et al. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia. 2020;34(1):151\u201366.","journal-title":"Leukemia"},{"issue":"23","key":"1673_CR78","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","volume":"3","author":"K Wienand","year":"2019","unstructured":"Wienand K, Chapuy B, Stewart C, Dunford AJ, Wu D, Kim J, Kamburov A, Wood TR, Cader FZ, Ducar MD, et al. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv. 2019;3(23):4065\u201380.","journal-title":"Blood Adv"},{"issue":"22","key":"1673_CR79","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","volume":"131","author":"E Tiacci","year":"2018","unstructured":"Tiacci E, Ladewig E, Schiavoni G, Penson A, Fortini E, Pettirossi V, Wang Y, Rosseto A, Venanzi A, Vlasevska S, et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood. 2018;131(22):2454\u201365.","journal-title":"Blood"},{"issue":"7","key":"1673_CR80","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","volume":"125","author":"J Reichel","year":"2015","unstructured":"Reichel J, Chadburn A, Rubinstein PG, Giulino-Roth L, Tam W, Liu Y, Gaiolla R, Eng K, Brody J, Inghirami G, et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood. 2015;125(7):1061\u201372.","journal-title":"Blood"},{"issue":"1","key":"1673_CR81","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3324\/haematol.2019.237719","volume":"106","author":"V Camus","year":"2021","unstructured":"Camus V, Viennot M, Lequesne J, Viailly PJ, Bohers E, Bessi L, Marcq B, Etancelin P, Dubois S, Picquenot JM, et al. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. Haematologica. 2021;106(1):154\u201362.","journal-title":"Haematologica"},{"issue":"3","key":"1673_CR82","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1158\/2643-3230.BCD-22-0128","volume":"4","author":"F Maura","year":"2023","unstructured":"Maura F, Ziccheddu B, Xiang JZ, Bhinder B, Rosiene J, Abascal F, Maclachlan KH, Eng KW, Uppal M, He F, et al. Molecular evolution of classic Hodgkin lymphoma revealed through whole-genome sequencing of Hodgkin and Reed Sternberg cells. Blood Cancer Discov. 2023;4(3):208\u201327.","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"1673_CR83","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/leu.2015.328","volume":"30","author":"S Hartmann","year":"2016","unstructured":"Hartmann S, Schuhmacher B, Rausch T, Fuller L, Doring C, Weniger M, Lollies A, Weiser C, Thurner L, Rengstl B, et al. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia. 2016;30(4):844\u201353.","journal-title":"Leukemia"},{"issue":"1","key":"1673_CR84","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3324\/haematol.2009.010157","volume":"95","author":"MA Schumacher","year":"2010","unstructured":"Schumacher MA, Schmitz R, Brune V, Tiacci E, Doring C, Hansmann ML, Siebert R, Kuppers R. Mutations in the genes coding for the NF-kappaB regulating factors IkappaBalpha and A20 are uncommon in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma. Haematologica. 2010;95(1):153\u20137.","journal-title":"Haematologica"},{"issue":"9","key":"1673_CR85","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","volume":"36","author":"EM Lauer","year":"2022","unstructured":"Lauer EM, Mutter J, Scherer F. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. Leukemia. 2022;36(9):2151\u201364.","journal-title":"Leukemia"},{"key":"1673_CR86","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pathol-050520-044652","volume":"18","author":"JG Schroers-Martin","year":"2023","unstructured":"Schroers-Martin JG, Alig S, Garofalo A, Tessoulin B, Sugio T, Alizadeh AA. Molecular monitoring of lymphomas. Annu Rev Pathol. 2023;18:149\u201380.","journal-title":"Annu Rev Pathol"},{"issue":"10","key":"1673_CR87","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/PAI.0000000000000020","volume":"22","author":"C Jimenez","year":"2014","unstructured":"Jimenez C, Chillon Mdel C, Balanzategui A, Puig N, Sebastian E, Alcoceba M, Sarasquete ME, Conde IP, Corral R, Marin LA, et al. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction. Appl Immunohistochem Mol Morphol. 2014;22(10):768\u201373.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"9","key":"1673_CR88","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/JOP.19.00691","volume":"16","author":"S Huet","year":"2020","unstructured":"Huet S, Salles G. Potential of circulating tumor DNA for the management of patients with lymphoma. JCO Oncol Pract. 2020;16(9):561\u20138.","journal-title":"JCO Oncol Pract"},{"issue":"15","key":"1673_CR89","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1073\/pnas.1133470100","volume":"100","author":"D Dressman","year":"2003","unstructured":"Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003;100(15):8817\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"1673_CR90","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood.V78.11.3021.3021","volume":"78","author":"D Billadeau","year":"1991","unstructured":"Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood. 1991;78(11):3021\u20139.","journal-title":"Blood"},{"key":"1673_CR91","doi-asserted-by":"crossref","unstructured":"Galimberti S, Balducci S, Guerrini F, Del Re M, Cacciola R. Digital droplet PCR in hematologic malignancies: a new useful molecular tool. Diagnostics (Basel). 2022;12(6).","DOI":"10.3390\/diagnostics12061305"},{"issue":"19","key":"1673_CR92","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-17-1439","volume":"23","author":"Y Khagi","year":"2017","unstructured":"Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res. 2017;23(19):5729\u201336.","journal-title":"Clin Cancer Res"},{"key":"1673_CR93","doi-asserted-by":"crossref","unstructured":"Chen Y, De Spiegelaere W, Trypsteen W, Gleerup D, Vandesompele J, Lievens A, Vynck M, Thas O. Benchmarking digital PCR partition classification methods with empirical and simulated duplex data. Brief Bioinform. 2024;25(3).","DOI":"10.1093\/bib\/bbae120"},{"key":"1673_CR94","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-1-62703-357-2_14","volume":"999","author":"CC Yin","year":"2013","unstructured":"Yin CC, Luthra R. Molecular detection of t(11;14)(q13;q32) in mantle cell lymphoma. Methods Mol Biol. 2013;999:211\u20136.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"1673_CR95","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3892\/etm.2020.8695","volume":"20","author":"K Chen","year":"2020","unstructured":"Chen K, Ma Y, Ding T, Zhang X, Chen B, Guan M. Effectiveness of digital PCR for MYD88(L265P) detection in vitreous fluid for primary central nervous system lymphoma diagnosis. Exp Ther Med. 2020;20(1):301\u20138.","journal-title":"Exp Ther Med"},{"issue":"5","key":"1673_CR96","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/clinchem\/hvab274","volume":"68","author":"TV Henriksen","year":"2022","unstructured":"Henriksen TV, Drue SO, Frydendahl A, Demuth C, Rasmussen MH, Reinert T, Pedersen JS, Andersen CL. Error characterization and statistical modeling improves circulating tumor DNA detection by droplet digital PCR. Clin Chem. 2022;68(5):657\u201367.","journal-title":"Clin Chem"},{"issue":"12","key":"1673_CR97","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39(12):1537\u201347.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"1673_CR98","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nrg2302","volume":"9","author":"AL McGuire","year":"2008","unstructured":"McGuire AL, Caulfield T, Cho MK. Research ethics and the challenge of whole-genome sequencing. Nat Rev Genet. 2008;9(2):152\u20136.","journal-title":"Nat Rev Genet"},{"issue":"5","key":"1673_CR99","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548\u201354.","journal-title":"Nat Med"},{"issue":"17","key":"1673_CR100","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-13-3231","volume":"20","author":"D Wu","year":"2014","unstructured":"Wu D, Emerson RO, Sherwood A, Loh ML, Angiolillo A, Howie B, Vogt J, Rieder M, Kirsch I, Carlson C, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res. 2014;20(17):4540\u20138.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1673_CR101","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jmoldx.2017.11.010","volume":"20","author":"SS Hung","year":"2018","unstructured":"Hung SS, Meissner B, Chavez EA, Ben-Neriah S, Ennishi D, Jones MR, Shulha HP, Chan FC, Boyle M, Kridel R, et al. Assessment of capture and amplicon-based approaches for the development of a targeted next-generation sequencing pipeline to personalize lymphoma management. J Mol Diagn. 2018;20(2):203\u201314.","journal-title":"J Mol Diagn"},{"issue":"12","key":"1673_CR102","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1158\/1078-0432.CCR-15-2305","volume":"22","author":"S Dubois","year":"2016","unstructured":"Dubois S, Viailly PJ, Mareschal S, Bohers E, Bertrand P, Ruminy P, Maingonnat C, Jais JP, Peyrouze P, Figeac M, et al. Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clin Cancer Res. 2016;22(12):2919\u201328.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"1673_CR103","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","volume":"120","author":"M Faham","year":"2012","unstructured":"Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E, Pui CH, Campana D. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173\u201380.","journal-title":"Blood"},{"issue":"24","key":"1673_CR104","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","volume":"125","author":"DM Kurtz","year":"2015","unstructured":"Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, Takahashi K, Glover C, Keane C, Kihira S, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125(24):3679\u201387.","journal-title":"Blood"},{"issue":"5","key":"1673_CR105","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjh.17251","volume":"193","author":"R Lakhotia","year":"2021","unstructured":"Lakhotia R, Roschewski M. Circulating tumour DNA in B-cell lymphomas: current state and future prospects. Br J Haematol. 2021;193(5):867\u201381.","journal-title":"Br J Haematol"},{"issue":"5","key":"1673_CR106","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nbt.3520","volume":"34","author":"AM Newman","year":"2016","unstructured":"Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, Stehr H, Liu CL, Bratman SV, Say C, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547\u201355.","journal-title":"Nat Biotechnol"},{"issue":"28","key":"1673_CR107","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845\u201353.","journal-title":"J Clin Oncol"},{"key":"1673_CR108","doi-asserted-by":"publisher","first-page":"716281","DOI":"10.3389\/fmicb.2021.716281","volume":"12","author":"C Chen","year":"2021","unstructured":"Chen C, Liu Z, Zhou W, Tian H, Huang J, Yuan H, Yu H. Comparison of the fermentation activities and volatile flavor profiles of Chinese rice wine fermented using an artificial starter, a traditional JIUYAO and a commercial starter. Front Microbiol. 2021;12:716281.","journal-title":"Front Microbiol"},{"issue":"6","key":"1673_CR109","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1309\/AJCP5TWORA0TMXGL","volume":"138","author":"JA Laurini","year":"2012","unstructured":"Laurini JA, Aoun P, Iqbal J, Chan W, Greiner TC. Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders. Am J Clin Pathol. 2012;138(6):877\u201383.","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"1673_CR110","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3324\/haematol.2019.238766","volume":"106","author":"H Larose","year":"2021","unstructured":"Larose H, Prokoph N, Matthews JD, Schlederer M, Hogler S, Alsulami AF, Ducray SP, Nuglozeh E, Fazaludeen FMS, Elmouna A, et al. Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica. 2021;106(6):1693\u2013704.","journal-title":"Haematologica"},{"issue":"2","key":"1673_CR111","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00401-016-1664-8","volume":"133","author":"T Nakamura","year":"2017","unstructured":"Nakamura T, Yamashita S, Fukumura K, Nakabayashi J, Tanaka K, Tamura K, Tateishi K, Kinoshita M, Fukushima S, Takami H, et al. Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. Acta Neuropathol. 2017;133(2):321\u20134.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1673_CR112","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13148-016-0261-y","volume":"8","author":"LS Kristensen","year":"2016","unstructured":"Kristensen LS, Hansen JW, Kristensen SS, Tholstrup D, Harslof LB, Pedersen OB, De Nully Brown P, Gronbaek K. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin Epigenetics. 2016;8(1):95.","journal-title":"Clin Epigenetics"},{"issue":"2","key":"1673_CR113","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1158\/1078-0432.CCR-20-2558","volume":"27","author":"A Rivas-Delgado","year":"2021","unstructured":"Rivas-Delgado A, Nadeu F, Enjuanes A, Casanueva-Eliceiry S, Mozas P, Magnano L, Castrej\u00f3n de Anta N, Rovira J, Dlouhy I, Mart\u00edn S, et al. Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study. Clin Cancer Res. 2021;27(2):513\u201321.","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"1673_CR114","first-page":"4013","volume":"130","author":"S Daigle","year":"2017","unstructured":"Daigle S, McDonald AA, Morschhauser F, Salles G, Ribrag V, McKay P, Tilly H, Schmitt A, Gerecitano J, Fruchart C, et al. Discovery of candidate predictors of response to Tazemetostat in diffuse large B-cell lymphoma and follicular lymphoma using NGS technology on ctDNA samples collected Pre-treatment. Blood. 2017;130(Supplement 1):4013\u20134013.","journal-title":"Blood"},{"issue":"22","key":"1673_CR115","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1182\/blood.V128.22.2930.2930","volume":"128","author":"DM Kurtz","year":"2016","unstructured":"Kurtz DM, Scherer F, Newman AM, Craig A, Jin M, Stehr H, Chabon JJ, Esfahani M, Liu CL, Zhou L, et al. Noninvasive detection of BCL2, BCL6, and MYC Translocations in diffuse large B-cell lymphoma. Blood. 2016;128(22):2930\u20132930.","journal-title":"Blood"},{"issue":"8","key":"1673_CR116","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922\u20136.","journal-title":"Nat Med"},{"issue":"1","key":"1673_CR117","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","volume":"41","author":"BJ Sworder","year":"2023","unstructured":"Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CW, Shahrokh Esfahani M, Olsen MN, Hamilton J, et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell. 2023;41(1):210\u2013e225215.","journal-title":"Cancer Cell"},{"issue":"22","key":"1673_CR118","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1182\/bloodadvances.2021004528","volume":"5","author":"A Bruscaggin","year":"2021","unstructured":"Bruscaggin A, di Bergamo LT, Spina V, Hodkinson B, Forestieri G, Bonfiglio F, Condoluci A, Wu W, Pirosa MC, Faderl MR, et al. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. Blood Adv. 2021;5(22):4674\u201385.","journal-title":"Blood Adv"},{"issue":"3","key":"1673_CR119","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/bjh.17894","volume":"196","author":"S Zhang","year":"2022","unstructured":"Zhang S, Zhang T, Liu H, Zhao J, Zhou H, Su X, Liu X, Li L, Qiu L, Qian Z, et al. Tracking the evolution of untreated high-intermediate\/high-risk diffuse large B-cell lymphoma by circulating tumour DNA. Br J Haematol. 2022;196(3):617\u201328.","journal-title":"Br J Haematol"},{"issue":"5","key":"1673_CR120","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","volume":"16","author":"M Roschewski","year":"2015","unstructured":"Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, Shovlin M, Jaffe ES, Staudt LM, Lai C, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541\u20139.","journal-title":"Lancet Oncol"},{"issue":"27","key":"1673_CR121","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.21.00377","volume":"39","author":"MJ Frank","year":"2021","unstructured":"Frank MJ, Hossain NM, Bukhari A, Dean E, Spiegel JY, Claire GK, Kirsch I, Jacob AP, Mullins CD, Lee LW, et al. Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial. J Clin Oncol. 2021;39(27):3034\u201343.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1673_CR122","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood.2021012852","volume":"139","author":"L Meriranta","year":"2022","unstructured":"Meriranta L, Alkodsi A, Pasanen A, Lepist\u00f6 M, Mapar P, Blaker YN, J\u00f8rgensen J, Karjalainen-Lindsberg ML, Fiskvik I, Mikalsen LTG, et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 2022;139(12):1863\u201377.","journal-title":"Blood"},{"issue":"3","key":"1673_CR123","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1080\/10428194.2021.1999441","volume":"63","author":"M Li","year":"2022","unstructured":"Li M, Ding N, Mi L, Shi Y, Du X, Yi Y, Yang L, Liu W, Zhu J. Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients. Leuk Lymphoma. 2022;63(3):608\u201317.","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"1673_CR124","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1200\/JCO.20.02573","volume":"39","author":"S Alig","year":"2021","unstructured":"Alig S, Macaulay CW, Kurtz DM, D\u00fchrsen U, H\u00fcttmann A, Schmitz C, Jin MC, Sworder BJ, Garofalo A, Shahrokh Esfahani M, et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-Cell lymphoma. J Clin Oncol. 2021;39(23):2605\u201316.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1673_CR125","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","volume":"130","author":"RO Casasnovas","year":"2017","unstructured":"Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, Tricot S, Gabarre J, Andre M, Fruchart C, et al. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood. 2017;130(11):1315\u201326.","journal-title":"Blood"},{"issue":"2","key":"1673_CR126","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3324\/haematol.2016.154039","volume":"102","author":"M Hertzberg","year":"2017","unstructured":"Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, et al. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica. 2017;102(2):356\u201363.","journal-title":"Haematologica"},{"issue":"31","key":"1673_CR127","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","volume":"35","author":"JP Leonard","year":"2017","unstructured":"Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, et al. Randomized phase II study of R-CHOP with or without Bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3538\u201346.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1673_CR128","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","volume":"28","author":"CH Moskowitz","year":"2010","unstructured":"Moskowitz CH, Sch\u00f6der H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, Straus D, Noy A, Palomba ML, O\u2019Connor OA, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28(11):1896\u2013903.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1673_CR129","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, \u00d6zcan M, Hong X, Zhu J, Jin J, et al. ROBUST: a phase III study of Lenalidomide plus R-CHOP Versus Placebo Plus R-CHOP in previously untreated patients with ABC-Type diffuse large B-Cell lymphoma. J Clin Oncol. 2021;39(12):1317\u201328.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1673_CR130","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","volume":"34","author":"G Kovacs","year":"2016","unstructured":"Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G, Ritgen M, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol. 2016;34(31):3758\u201365.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1673_CR131","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1182\/blood-2016-05-714162","volume":"128","author":"M Kwok","year":"2016","unstructured":"Kwok M, Rawstron AC, Varghese A, Evans PA, O\u2019Connor SJ, Doughty C, Newton DJ, Moreton P, Hillmen P. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016;128(24):2770\u20133.","journal-title":"Blood"},{"issue":"1","key":"1673_CR132","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12916-022-02562-3","volume":"20","author":"M Li","year":"2022","unstructured":"Li M, Mi L, Wang C, Wang X, Zhu J, Qi F, Yu H, Ye Y, Wang D, Cao J, et al. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy. BMC Med. 2022;20(1):369.","journal-title":"BMC Med"},{"issue":"3","key":"1673_CR133","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","volume":"178","author":"DM Kurtz","year":"2019","unstructured":"Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, D\u00fchrsen U, H\u00fcttmann A, Casasnovas O, et al. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell. 2019;178(3):699\u2013e713619.","journal-title":"Cell"},{"issue":"1","key":"1673_CR134","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/bjh.19458","volume":"205","author":"M Alcoceba","year":"2024","unstructured":"Alcoceba M, Stewart JP, Garc\u00eda-\u00c1lvarez M, D\u00edaz LG, Jim\u00e9nez C, Medina A, Chill\u00f3n MC, Gazdova J, Blanco O, D\u00edaz FJ, et al. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease. Br J Haematol. 2024;205(1):109\u201321.","journal-title":"Br J Haematol"},{"issue":"6","key":"1673_CR135","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1182\/bloodadvances.2021006415","volume":"6","author":"AF Herrera","year":"2022","unstructured":"Herrera AF, Tracy S, Croft B, Opat S, Ray J, Lovejoy AF, Musick L, Paulson JN, Sehn LH, Jiang Y. Risk profiling of patients with relapsed\/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood Adv. 2022;6(6):1651\u201360.","journal-title":"Blood Adv"},{"issue":"2","key":"1673_CR136","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1182\/blood-2016-02-699520","volume":"128","author":"SE Assouline","year":"2016","unstructured":"Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, Tosikyan A, Kukreti V, Kezouh A, Petrogiannis-Haliotis T, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016;128(2):185\u201394.","journal-title":"Blood"},{"issue":"31","key":"1673_CR137","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","volume":"32","author":"CA Thompson","year":"2014","unstructured":"Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, Chassagne-Cl\u00e9ment C, Inwards DJ, Gargi T, Johnston PB, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014;32(31):3506\u201312.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1673_CR138","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1200\/JCO.2014.58.5729","volume":"33","author":"SF Huntington","year":"2015","unstructured":"Huntington SF, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol. 2015;33(13):1467\u201374.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1673_CR139","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","volume":"6","author":"R Lakhotia","year":"2022","unstructured":"Lakhotia R, Melani C, Dunleavy K, Pittaluga S, Saba N, Lindenberg L, Mena E, Bergvall E, Lucas AN, Jacob A, et al. Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. Blood Adv. 2022;6(8):2667\u201380.","journal-title":"Blood Adv"},{"issue":"1","key":"1673_CR140","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, Thijssen R, Yeh P, Wong SQ, Ftouni S, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019;25(1):119\u201329.","journal-title":"Nat Med"},{"issue":"1","key":"1673_CR141","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1186\/s12885-022-10070-z","volume":"22","author":"C Mart\u00ednez-Laperche","year":"2022","unstructured":"Mart\u00ednez-Laperche C, Sanz-Villanueva L, D\u00edaz Crespo FJ, Mu\u00f1iz P, Mart\u00edn Rojas R, Carbonell D, Chicano M, Su\u00e1rez-Gonz\u00e1lez J, Men\u00e1rguez J, Kwon M, et al. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. BMC Cancer. 2022;22(1):982.","journal-title":"BMC Cancer"},{"issue":"3","key":"1673_CR142","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/joim.13674","volume":"294","author":"\u00c1 Nagy","year":"2023","unstructured":"Nagy \u00c1, B\u00e1tai B, Kiss L, Gr\u00f3f S, Kir\u00e1ly PA, J\u00f3na \u00c1, Demeter J, S\u00e1nta H, B\u00e1tai \u00c1, Pettendi P, et al. Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma. J Intern Med. 2023;294(3):295\u2013313.","journal-title":"J Intern Med"},{"issue":"18","key":"1673_CR143","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","volume":"122","author":"C B\u00f6d\u00f6r","year":"2013","unstructured":"B\u00f6d\u00f6r C, Grossmann V, Popov N, Okosun J, O\u2019Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122(18):3165\u20138.","journal-title":"Blood"},{"issue":"2","key":"1673_CR144","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","volume":"46","author":"J Okosun","year":"2014","unstructured":"Okosun J, B\u00f6d\u00f6r C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46(2):176\u201381.","journal-title":"Nat Genet"},{"key":"1673_CR145","doi-asserted-by":"publisher","first-page":"870487","DOI":"10.3389\/fonc.2022.870487","volume":"12","author":"T Hatipo\u011flu","year":"2022","unstructured":"Hatipo\u011flu T, Esmeray S\u00f6nmez E, Hu X, Yuan H, Danyeli AE, \u015eeyhanl\u0131 A, \u00d6nal-S\u00fczek T, Zhang W, Akman B, Olgun A, et al. Plasma concentrations and cancer-associated mutations in cell-free circulating DNA of treatment-naive Follicular lymphoma for improved non-invasive diagnosis and prognosis. Front Oncol. 2022;12:870487.","journal-title":"Front Oncol"},{"key":"1673_CR146","doi-asserted-by":"publisher","first-page":"1066808","DOI":"10.3389\/fgene.2023.1066808","volume":"14","author":"M Zhao","year":"2023","unstructured":"Zhao M, Li Q, Yang J, Zhang M, Liu X, Zhang H, Huang Y, Li J, Bao J, Wang J, et al. Application of circulating tumour DNA in terms of prognosis prediction in Chinese follicular lymphoma patients. Front Genet. 2023;14:1066808.","journal-title":"Front Genet"},{"key":"1673_CR147","doi-asserted-by":"crossref","unstructured":"Yoon SE, Shin SH, Nam DK, Cho J, Kim WS, Kim SJ. Feasibility of circulating tumor DNA analysis in patients with Follicular Lymphoma. Cancer Res Treat. 2024.","DOI":"10.4143\/crt.2023.869"},{"issue":"7","key":"1673_CR148","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","volume":"2","author":"MH Delfau-Larue","year":"2018","unstructured":"Delfau-Larue MH, van der Gucht A, Dupuis J, Jais JP, Nel I, Beldi-Ferchiou A, Hamdane S, Benmaad I, Laboure G, Verret B, et al. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma. Blood Adv. 2018;2(7):807\u201316.","journal-title":"Blood Adv"},{"issue":"5","key":"1673_CR149","doi-asserted-by":"publisher","first-page":"8765","DOI":"10.18632\/oncotarget.14448","volume":"8","author":"C Sarkozy","year":"2017","unstructured":"Sarkozy C, Huet S, Carlton VE, Fabiani B, Delmer A, Jardin F, Delfau-Larue MH, Hacini M, Ribrag V, Guidez S, et al. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget. 2017;8(5):8765\u201374.","journal-title":"Oncotarget"},{"issue":"1","key":"1673_CR150","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","volume":"29","author":"I Fern\u00e1ndez-Miranda","year":"2023","unstructured":"Fern\u00e1ndez-Miranda I, Pedrosa L, Llanos M, Franco FF, G\u00f3mez S, Mart\u00edn-Acosta P, Garc\u00eda-Arroyo FR, Gum\u00e1 J, Horcajo B, Ballesteros AK, et al. Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study. Clin Cancer Research: Official J Am Association Cancer Res. 2023;29(1):209\u201320.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"1673_CR151","doi-asserted-by":"publisher","first-page":"1188818","DOI":"10.3389\/fimmu.2023.1188818","volume":"14","author":"A Jim\u00e9nez-Ubieto","year":"2023","unstructured":"Jim\u00e9nez-Ubieto A, Mart\u00edn-Mu\u00f1oz A, Poza M, Dorado S, Garc\u00eda-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodr\u00edguez A, et al. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients. Front Immunol. 2023;14:1188818.","journal-title":"Front Immunol"},{"issue":"14","key":"1673_CR152","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1200\/JCO.2010.32.7577","volume":"29","author":"S Montoto","year":"2011","unstructured":"Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol. 2011;29(14):1827\u201334.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1673_CR153","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/2159-8290.CD-23-0111","volume":"13","author":"JG Schroers-Martin","year":"2023","unstructured":"Schroers-Martin JG, Soo J, Brisou G, Scherer F, Kurtz DM, Sworder BJ, Khodadoust MS, Jin MC, Bru A, Liu CL, et al. Tracing founder mutations in circulating and tissue-resident Follicular lymphoma precursors. Cancer Discov. 2023;13(6):1310\u201323.","journal-title":"Cancer Discov"},{"issue":"14","key":"1673_CR154","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1182\/bloodadvances.2022009412","volume":"7","author":"M Tatarczuch","year":"2023","unstructured":"Tatarczuch M, Waltham M, Shortt J, Polekhina G, Hawkes EA, Ho S-J, Trotman J, Brasacchio D, Co M, Li J, et al. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma. Blood Adv. 2023;7(14):3531\u20139.","journal-title":"Blood Adv"},{"issue":"2","key":"1673_CR155","doi-asserted-by":"publisher","first-page":"597","DOI":"10.4143\/crt.2021.752","volume":"54","author":"SE Yoon","year":"2022","unstructured":"Yoon SE, Kim YJ, Shim JH, Park D, Cho J, Ko YH, Park WY, Mun YC, Lee KE, Cho D, et al. Plasma circulating tumor DNA in patients with primary central nervous system lymphoma. Cancer Res Treat. 2022;54(2):597\u2013612.","journal-title":"Cancer Res Treat"},{"issue":"3","key":"1673_CR156","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11060-013-1182-7","volume":"114","author":"J He","year":"2013","unstructured":"He J, Wu J, Jiao Y, Rodriguez FJ, Blakeley JO, Kinzler KW, Papadopoulos N, Vogelstein B, Holdhoff M. Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma. J Neurooncol. 2013;114(3):275\u20139.","journal-title":"J Neurooncol"},{"issue":"2","key":"1673_CR157","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3324\/haematol.2019.241208","volume":"106","author":"S Bobillo","year":"2021","unstructured":"Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, Rubio-Perez C, Taz\u00f3n-Vega B, Palacio C, Carabia J, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2021;106(2):513\u201321.","journal-title":"Haematologica"},{"issue":"1","key":"1673_CR158","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12885-019-5394-x","volume":"19","author":"AK Hickmann","year":"2019","unstructured":"Hickmann AK, Frick M, Hadaschik D, Battke F, Bittl M, Ganslandt O, Biskup S, D\u00f6cker D. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas. BMC Cancer. 2019;19(1):192.","journal-title":"BMC Cancer"},{"issue":"9","key":"1673_CR159","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1200\/JCO.22.00826","volume":"41","author":"JA Mutter","year":"2023","unstructured":"Mutter JA, Alig SK, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM, K\u00fchn J, Bleul S, Olsen M, Liu CL, et al. Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas. J Clin Oncol. 2023;41(9):1684\u201394.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1673_CR160","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3324\/haematol.2021.279908","volume":"107","author":"X Wang","year":"2022","unstructured":"Wang X, Su W, Gao Y, Feng Y, Wang X, Chen X, Hu Y, Ma Y, Ou Q, Liang D, et al. A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas. Haematologica. 2022;107(9):2154\u201362.","journal-title":"Haematologica"},{"issue":"5","key":"1673_CR161","doi-asserted-by":"publisher","first-page":"7989","DOI":"10.18632\/oncotarget.14008","volume":"8","author":"AK Cani","year":"2017","unstructured":"Cani AK, Hovelson DH, Demirci H, Johnson MW, Tomlins SA, Rao RC. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies. Oncotarget. 2017;8(5):7989\u201398.","journal-title":"Oncotarget"},{"issue":"10","key":"1673_CR162","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jamaophthalmol.2018.2887","volume":"136","author":"LS Hiemcke-Jiwa","year":"2018","unstructured":"Hiemcke-Jiwa LS, Ten Dam-van Loon NH, Leguit RJ, Nierkens S, Ossewaarde-van Norel J, de Boer JH, Roholl FF, de Weger RA, Huibers MMH, de Groot-Mijnes JDF, et al. Potential diagnosis of vitreoretinal lymphoma by detection of MYD88 mutation in aqueous humor with ultrasensitive droplet digital polymerase chain reaction. JAMA Ophthalmol. 2018;136(10):1098\u2013104.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1673_CR163","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13148-021-01091-9","volume":"13","author":"BM Downs","year":"2021","unstructured":"Downs BM, Ding W, Cope LM, Umbricht CB, Li W, He H, Ke X, Holdhoff M, Bettegowda C, Tao W, et al. Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors. Clin Epigenetics. 2021;13(1):104.","journal-title":"Clin Epigenetics"},{"issue":"6","key":"1673_CR164","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1182\/blood.2023022020","volume":"143","author":"JM Heger","year":"2024","unstructured":"Heger JM, Mattlener J, Schneider J, G\u00f6del P, Sieg N, Ullrich F, Lewis R, Bucaciuc-Mracica T, Schwarz RF, Rue\u00df D, et al. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA. Blood. 2024;143(6):522\u201334.","journal-title":"Blood"},{"issue":"1","key":"1673_CR165","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/cas.13450","volume":"109","author":"K Hattori","year":"2018","unstructured":"Hattori K, Sakata-Yanagimoto M, Suehara Y, Yokoyama Y, Kato T, Kurita N, Nishikii H, Obara N, Takano S, Ishikawa E, et al. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci. 2018;109(1):225\u201330.","journal-title":"Cancer Sci"},{"issue":"5","key":"1673_CR166","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00277-021-04686-7","volume":"101","author":"C Iriyama","year":"2022","unstructured":"Iriyama C, Murate K, Iba S, Okamoto A, Yamamoto H, Kanbara A, Sato A, Iwata E, Yamada R, Okamoto M, et al. Detection of circulating tumor DNA in cerebrospinal fluid prior to diagnosis of spinal cord lymphoma by flow cytometric and cytologic analyses. Ann Hematol. 2022;101(5):1157\u20139.","journal-title":"Ann Hematol"},{"key":"1673_CR167","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fonc.2018.00382","volume":"8","author":"S Zorofchian","year":"2018","unstructured":"Zorofchian S, Lu G, Zhu JJ, Duose DY, Windham J, Esquenazi Y, Ballester LY. Detection of the MYD88 p.L265P mutation in the CSF of a patient with secondary Central Nervous System Lymphoma. Front Oncol. 2018;8:382.","journal-title":"Front Oncol"},{"issue":"5","key":"1673_CR168","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/bjh.15674","volume":"185","author":"LS Hiemcke-Jiwa","year":"2019","unstructured":"Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ, Bromberg JEC, Nierkens S, Jiwa NM, Minnema MC, Huibers MMH. MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma. Br J Haematol. 2019;185(5):974\u20137.","journal-title":"Br J Haematol"},{"issue":"7","key":"1673_CR169","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41375-024-02279-7","volume":"38","author":"JH Liang","year":"2024","unstructured":"Liang JH, Wu YF, Shen HR, Li Y, Liang JH, Gao R, Hua W, Shang CY, Du KX, Xing TY, et al. Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma. Leukemia. 2024;38(7):1541\u201352.","journal-title":"Leukemia"},{"issue":"24","key":"1673_CR170","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.1182\/bloodadvances.2021004512","volume":"5","author":"AJ Olszewski","year":"2021","unstructured":"Olszewski AJ, Chorzalska AD, Petersen M, Ollila TA, Zayac A, Kurt H, Treaba DO, Reagan JL, Hsu A, Egan PC, et al. Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma. Blood Adv. 2021;5(24):5525\u201335.","journal-title":"Blood Adv"},{"issue":"10","key":"1673_CR171","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1080\/10428194.2020.1768382","volume":"61","author":"M Hayashida","year":"2020","unstructured":"Hayashida M, Maekawa F, Chagi Y, Iioka F, Kobashi Y, Watanabe M, Ohno H. Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the RHOA(G17V) and IDH2(R172) hot-spot mutations in plasma cell-free DNA as liquid biopsy for the diagnosis of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2020;61(10):2389\u201398.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"1673_CR172","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00277-017-3038-2","volume":"96","author":"M Sakata-Yanagimoto","year":"2017","unstructured":"Sakata-Yanagimoto M, Nakamoto-Matsubara R, Komori D, Nguyen TB, Hattori K, Nanmoku T, Kato T, Kurita N, Yokoyama Y, Obara N, et al. Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma. Ann Hematol. 2017;96(9):1471\u20135.","journal-title":"Ann Hematol"},{"issue":"11","key":"1673_CR173","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/bloodadvances.2020001637","volume":"5","author":"F Qi","year":"2021","unstructured":"Qi F, Cao Z, Chen B, Chai Y, Lin J, Ye J, Wei Y, Liu H, Han-Zhang H, Mao X, et al. Liquid biopsy in extranodal NK\/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring. Blood Adv. 2021;5(11):2505\u201314.","journal-title":"Blood Adv"},{"issue":"11","key":"1673_CR174","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/bloodadvances.2019001075","volume":"4","author":"B Ottolini","year":"2020","unstructured":"Ottolini B, Nawaz N, Trethewey CS, Mamand S, Allchin RL, Dillon R, Fields PA, Ahearne MJ, Wagner SD. Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma. Blood Adv. 2020;4(11):2392\u2013403.","journal-title":"Blood Adv"},{"key":"1673_CR175","doi-asserted-by":"publisher","first-page":"1109715","DOI":"10.3389\/fonc.2023.1109715","volume":"13","author":"JJ Kim","year":"2023","unstructured":"Kim JJ, Kim HY, Choi Z, Hwang SY, Jeong H, Choi JR, Yoon SE, Kim WS, Kim SH, Kim HJ, et al. In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer\/T-cell lymphomas. Front Oncol. 2023;13:1109715.","journal-title":"Front Oncol"},{"key":"1673_CR176","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40364-020-00205-4","volume":"8","author":"Q Li","year":"2020","unstructured":"Li Q, Zhang W, Li J, Xiong J, Liu J, Chen T, Wen Q, Zeng Y, Gao L, Gao L, et al. Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK\/T-cell lymphoma. Biomark Res. 2020;8:27.","journal-title":"Biomark Res"},{"issue":"1","key":"1673_CR177","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4143\/crt.2022.017","volume":"55","author":"SJ Kim","year":"2023","unstructured":"Kim SJ, Kim YJ, Yoon SE, Ryu KJ, Park B, Park D, Cho D, Kim HY, Cho J, Ko YH, et al. Circulating tumor DNA-based genotyping and monitoring for predicting disease relapses of patients with peripheral T-cell lymphomas. Cancer Res Treat. 2023;55(1):291\u2013303.","journal-title":"Cancer Res Treat"},{"issue":"20","key":"1673_CR178","first-page":"4198","volume":"5","author":"MD Miljkovic","year":"2021","unstructured":"Miljkovic MD, Melani C, Pittaluga S, Lakhotia R, Lucas N, Jacob A, Yusko E, Jaffe ES, Wilson WH, Roschewski M. Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL. Blood Adv. 2021;5(20):4198\u2013210.","journal-title":"Blood Adv"},{"key":"1673_CR179","unstructured":"Jin-Hua L, Wei H, Xin-Yi Z, Haorui S, Jia-Zhu W, Jun-Heng L, Liu-Qing Z, Hua Y, Yue L, Li W et al. Clinical implications of ctdna in residual disease assessment, prognosis prediction, disease monitoring for newly peripheral t-cell lymphoma patients. EHA. 2024."},{"issue":"1","key":"1673_CR180","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-024-01825-0","volume":"9","author":"Y Gao","year":"2024","unstructured":"Gao Y, He H, Li X, Zhang L, Xu W, Feng R, Li W, Xiao Y, Liu X, Chen Y, et al. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib\/II study. Signal Transduct Target Ther. 2024;9(1):121.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1673_CR181","doi-asserted-by":"publisher","first-page":"100859","DOI":"10.1016\/j.xcrm.2022.100859","volume":"4","author":"X-P Tian","year":"2023","unstructured":"Tian X-P, Zhang Y-C, Lin N-J, Wang L, Li Z-H, Guo H-G, Ma S-Y, An M-J, Yang J, Hong Y-H, et al. Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer\/T cell lymphoma. Cell Rep Med. 2023;4(2):100859.","journal-title":"Cell Rep Med"},{"issue":"9","key":"1673_CR182","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","volume":"101","author":"V Camus","year":"2016","unstructured":"Camus V, Stamatoullas A, Mareschal S, Viailly PJ, Sarafan-Vasseur N, Bohers E, Dubois S, Picquenot JM, Ruminy P, Maingonnat C, et al. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica. 2016;101(9):1094\u2013101.","journal-title":"Haematologica"},{"issue":"9","key":"1673_CR183","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/ajh.24451","volume":"91","author":"F Jardin","year":"2016","unstructured":"Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, Dubois S, Sola B, Ochmann M, Lemonnier F, et al. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. Am J Hematol. 2016;91(9):923\u201330.","journal-title":"Am J Hematol"},{"issue":"5","key":"1673_CR184","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41379-019-0428-0","volume":"33","author":"C Van Slambrouck","year":"2020","unstructured":"Van Slambrouck C, Huh J, Suh C, Song JY, Menon MP, Sohani AR, Duffield AS, Goldberg RC, Dama P, Kiyotani K, et al. Diagnostic utility of STAT6(YE361) expression in classical Hodgkin lymphoma and related entities. Mod Pathol. 2020;33(5):834\u201345.","journal-title":"Mod Pathol"},{"issue":"7","key":"1673_CR185","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1182\/bloodadvances.2020003039","volume":"5","author":"L Buedts","year":"2021","unstructured":"Buedts L, Wlodarska I, Finalet-Ferreiro J, Gheysens O, Dehaspe L, Tousseyn T, Fornecker LM, Lazarovici J, Casasnovas RO, Gac AC, et al. The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA. Blood Adv. 2021;5(7):1991\u20132002.","journal-title":"Blood Adv"},{"issue":"12","key":"1673_CR186","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/annonc\/mdx501","volume":"28","author":"J Garc\u00eda-Foncillas","year":"2017","unstructured":"Garc\u00eda-Foncillas J, Alba E, Aranda E, D\u00edaz-Rubio E, L\u00f3pez-L\u00f3pez R, Tabernero J, Vivancos A. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. Ann Oncol. 2017;28(12):2943\u20139.","journal-title":"Ann Oncol"},{"issue":"4","key":"1673_CR187","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/ijlh.13453","volume":"43","author":"RP Correia","year":"2021","unstructured":"Correia RP, Puga RD, Muto NH, Lee MLM, Torres DC, Hassan R, Bacal NS, Hamerschlak N, Campregher PV. High-throughput sequencing of immunoglobulin heavy chain for minimal residual disease detection in B-lymphoblastic leukemia. Int J Lab Hematol. 2021;43(4):724\u201331.","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"1673_CR188","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/bjh.14311","volume":"175","author":"AF Herrera","year":"2016","unstructured":"Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, Alyea EP, Carlton VE, Chen YB, Cutler CS, et al. Next-generation sequencing-based detection of circulating tumour DNA after allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016;175(5):841\u201350.","journal-title":"Br J Haematol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01673-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01673-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01673-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T09:56:51Z","timestamp":1741687011000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01673-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":188,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1673"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01673-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}